Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM)-Added trial

McMurray, J. et al. (2006) Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM)-Added trial. American Heart Journal, 151, pp. 985-991. (doi:10.1016/j.ahj.2006.02.028)

Full text not currently available from Enlighten.


Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:McMurray, Professor John
Authors: McMurray, J., Young, J., Dunlap, M., Granger, C., Hainer, J., Michelson, E., Earle, S., Olofsson, B., Ostergren, J., Yusuf, S., Swedberg, K., Pfeffer, M., and Invest, C.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
College of Medical Veterinary and Life Sciences
Journal Name:American Heart Journal

University Staff: Request a correction | Enlighten Editors: Update this record